Geneva  Switzerland  3 January 2008 – Allosteric modulation company Addex Pharmaceuticals (SWX:ADXN) announced today that it has entered an exclusive worldwide license agreement with Merck & Co  Inc ("Merck") to develop ADX63365  an orally available drug candidate for the potential treatment of schizophrenia and other undisclosed indications